INVITED REVIEW
Year : 2018  |  Volume : 20  |  Issue : 3  |  Page : 215-220

Bone-targeted therapies to reduce skeletal morbidity in prostate cancer


1 USC Keck School of Medicine, USC Norris Comprehensive Cancer Center, Genitourinary Oncology, Los Angeles, CA 90033, USA
2 Hunts Man Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA

Correspondence Address:
Dr. Tanya B Dorff
USC Keck School of Medicine, USC Norris Comprehensive Cancer Center, Genitourinary Oncology, Los Angeles, CA 90033, USA

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/aja.aja_12_18

Rights and Permissions

Bone metastases are the main driver of morbidity and mortality in advanced prostate cancer. Targeting the bone microenvironment, a key player in the pathogenesis of bone metastasis, has become one of the mainstays of therapy in men with advanced prostate cancer. This review will evaluate the data supporting the use of bone-targeted therapy, including (1) bisphosphonates such as zoledronic acid, which directly target osteoclasts, (2) denosumab, a receptor activator of nuclear factor-kappa B (RANK) ligand inhibitor, which targets a key component of bone stromal interaction, and (3) radium-223, an alpha-emitting calcium mimetic, which hones to the metabolically active areas of osteoblastic metastasis and induces double-strand breaks in the DNA. Denosumab has shown enhanced delay in skeletal-related events compared to zoledronic acid in patients with metastatic castration-resistant prostate cancer (mCRPC). Data are mixed with regard to pain control as a primary measure of efficacy. New data call into question dosing frequency, with quarterly dosing strategy potentially achieving similar effect compared to monthly dosing for zoledronic acid. In the case of radium-223, there are data for both pain palliation and improved overall survival in mCRPC. Further studies are needed to optimize timing and combination strategies for bone-targeted therapies. Ongoing studies will explore the impact of combining bone-targeted therapy with investigational therapeutic agents such as immunotherapy, for advanced prostate cancer. Future studies should strive to develop biomarkers of response, in order to improve efficacy and cost-effectiveness of these agents.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2983    
    Printed90    
    Emailed0    
    PDF Downloaded380    
    Comments [Add]    

Recommend this journal